Type I Interferon Receptor Deficiency Prevents Murine Sjogren's Syndrome

被引:35
作者
Szczerba, B. M. [1 ]
Rybakowska, P. D. [1 ]
Dey, P. [1 ]
Payerhin, K. M. [1 ]
Peck, A. B. [2 ]
Bagavant, H. [1 ,3 ]
Deshmukh, U. S. [1 ,3 ]
机构
[1] Univ Florida, Div Nephrol, Ctr Immun Inflammat & Regenerat Med, Gainesville, FL 32610 USA
[2] Univ Florida, Dept Pathol Immunol & Lab Med, Gainesville, FL USA
[3] Univ Virginia, Dept Pharmacol, HSC, Charlottesville, VA 22908 USA
基金
美国国家卫生研究院;
关键词
xerostomia; sialoadenitis; autoimmunity; salivary gland; mouse; interferons; SYNDROME-LIKE DISEASE; GENE-EXPRESSION; SALIVARY-GLANDS; IMMUNE-RESPONSES; INNATE IMMUNITY; MOUSE MODEL; MICE; ACTIVATION; PATHOGENESIS; UPDATE;
D O I
10.1177/0022034513483315
中图分类号
R78 [口腔科学];
学科分类号
1003 ;
摘要
In Sjogren's Syndrome (SS), inherent glandular defects, autoimmunity, and mononuclear cell infiltration within the salivary glands cause reduced salivation leading to xerostomia. Excessive production of type I interferons (IFN), triggered by environmental and genetic factors, is considered pathogenic in this disorder. However, whether type I IFN production is causative or an outcome of the disease process is not known. To address this question, we introduced a deficiency of interferon alpha receptor 1 (Ifnar1) into B6.Aec1Aec2 mice, which are known to have the genetic loci necessary for developing a SS-like disorder. This new mouse strain, B6.Aec1Aec2Ifnar1(-/-), lacking type I IFN-mediated signaling, was characterized for pilocarpine-induced salivation, the presence of serum autoantibodies, sialoadenitis, and dacryoadenitis. Compared with the B6.Aec1Aec2Ifnar1(+/+) (wild-type) mice, the B6.Aec1Aec2Ifnar1(-/-)(knockout) mice had significantly lower mononuclear cell infiltration in the salivary and lacrimal glands. The knockout mice were completely protected from salivary gland dysfunction. Surprisingly, they had a robust autoantibody response comparable with that of the wild-type mice. These findings demonstrate that, in the absence of type I IFN-mediated signaling, systemic autoantibody responses can be dissociated from glandular pathology. Our study suggests that, in genetically susceptible individuals, the type I IFN pathway can instigate certain features of SS.
引用
收藏
页码:444 / 449
页数:6
相关论文
共 50 条
[31]   Selenium deficiency is associated with polyneuropathy in primary Sjogren's syndrome [J].
Hirsch, S. ;
Skripuletz, T. ;
Seeliger, T. ;
Witte, T. ;
Thiele, T. .
CLINICAL NUTRITION ESPEN, 2022, 50 :212-217
[32]   The metalloproteinase ADAM17 and the epidermal growth factor receptor (EGFR) signaling drive the inflammatory epithelial response in Sjogren's syndrome [J].
Sisto, Margherita ;
Lisi, Sabrina ;
D'Amore, Massimo ;
Lofrumento, Dario Domenico .
CLINICAL AND EXPERIMENTAL MEDICINE, 2015, 15 (02) :215-225
[33]   Protective Role of Toll-like Receptor 3-Induced Type I Interferon in Murine Coronavirus Infection of Macrophages [J].
Mazaleuskaya, Liudmila ;
Veltrop, Rogier ;
Ikpeze, Nneka ;
Martin-Garcia, Julio ;
Navas-Martin, Sonia .
VIRUSES-BASEL, 2012, 4 (05) :901-923
[34]   X-linked ectodermal dysplasia receptor (XEDAR) gene silencing prevents caspase-3-mediated apoptosis in Sjogren's syndrome [J].
Sisto, Margherita ;
Lorusso, Loredana ;
Lisi, Sabrina .
CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 17 (01) :111-119
[35]   Partial Protection From Lupus-Like Disease by B-Cell Specific Type I Interferon Receptor Deficiency [J].
Keller, Emma J. ;
Patel, Neeva B. ;
Patt, Madeline ;
Nguyen, Jane K. ;
Jorgensen, Trine N. .
FRONTIERS IN IMMUNOLOGY, 2021, 11
[36]   Activation of the Interferon Pathway in Peripheral Blood of Patients with Sjogren's Syndrome [J].
Kimoto, Osamu ;
Sawada, Jin ;
Shimoyama, Kumiko ;
Suzuki, Daisuke ;
Nakamura, Satoki ;
Hayashi, Hdeharu ;
Ogawa, Noriyoshi .
JOURNAL OF RHEUMATOLOGY, 2011, 38 (02) :310-316
[37]   The clinical relevance of animal models in Sjogren's syndrome: the interferon signature from mouse to man [J].
Maria, Naomi I. ;
Vogelsang, Petra ;
Versnel, Marjan A. .
ARTHRITIS RESEARCH & THERAPY, 2015, 17
[38]   Aberrant signaling of immune cells in Sjogren's syndrome patient subgroups upon interferon stimulation [J].
Sarkar, Irene ;
Davies, Richard ;
Aarebrot, Anders K. ;
Solberg, Silje M. ;
Petrovic, Aleksandra ;
Joshi, Anagha M. ;
Bergum, Brith ;
Brun, Johan G. ;
Hammenfors, Daniel ;
Jonsson, Roland ;
Appel, Silke .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[39]   Inhibition of lysophosphatidic acid receptor ameliorates Sjogren's syndrome in NOD mice [J].
Park, Eunhye ;
Kim, Donghee ;
Lee, Song Mi ;
Jun, Hee-Sook .
ONCOTARGET, 2017, 8 (16) :27240-27251
[40]   Monocytes from Sjogren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis [J].
Hauk, V. ;
Fraccaroli, L. ;
Grasso, E. ;
Eimon, A. ;
Ramhorst, R. ;
Hubscher, O. ;
Perez Leiros, C. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2014, 177 (03) :662-670